GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » PB Ratio

Mira Pharmaceuticals (Mira Pharmaceuticals) PB Ratio : 4.14 (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mira Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-26), Mira Pharmaceuticals's share price is $0.885. Mira Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was $0.21. Hence, Mira Pharmaceuticals's PB Ratio of today is 4.14.

The historical rank and industry rank for Mira Pharmaceuticals's PB Ratio or its related term are showing as below:

MIRA' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 5.48
Current: 4.14

During the past 3 years, Mira Pharmaceuticals's highest PB Ratio was 5.48. The lowest was 0.00. And the median was 0.00.

MIRA's PB Ratio is ranked worse than
79.58% of 955 companies
in the Drug Manufacturers industry
Industry Median: 2 vs MIRA: 4.14

Back to Basics: PB Ratio


Mira Pharmaceuticals PB Ratio Historical Data

The historical data trend for Mira Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals PB Ratio Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
PB Ratio
- - 3.55

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 8.47 3.55 5.14

Competitive Comparison of Mira Pharmaceuticals's PB Ratio

For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mira Pharmaceuticals's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Mira Pharmaceuticals's PB Ratio falls into.



Mira Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Mira Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=0.885/0.214
=4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Mira Pharmaceuticals  (NAS:MIRA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Mira Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mira Pharmaceuticals (Mira Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.
Executives
Brian Patrick Mcnulty 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Frederick Daly director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
George Cappy 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
David C Vorhoff director C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Chapman Christopher C Jr director, officer: Executive Chairman C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Adam Kaplin officer: Pres. & Chief Scientific Off. C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Michelle Yanez officer: CFO, Secretary & Treasurer 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Hugh Iii Mccoll director 100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202
Christos Nicholoudis director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bradley Kroenig director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Erez Aminov director, officer: Chief Executive Officer C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Talhia Tuck director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bay Shore Trust 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173